Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3442252 | 1.00 | METAP2 (0.50) | METAP2ALDH1A1CYP3A4TP53TDP1 | |
| Hydrochloric Acid SCHEMBL2671869 | 0.98 | METAP2 (0.48) | METAP2ALDH1A1CYP3A4TP53TDP1 | |
| SCHEMBL16766999 | 0.88 | LMNA (0.36) | METAP2KEAP1MEN1KMT2AMAPT | |
| SCHEMBL1645103 | 0.77 | METAP2 (0.50) | METAP2ALPLMEN1KMT2AMAPT | |
| SCHEMBL989177 | 0.77 | CA12 (0.42) | ALDH1A1ALPLMEN1KMT2AMAPT | |
| SCHEMBL8486152 | 0.77 | LMNA (0.35) | MEN1KMT2ALMNA | |
| SCHEMBL9955 | 0.77 | METAP2 (0.50) | METAP2ALDH1A1CYP3A4TP53MEN1 | |
| SCHEMBL2765284 | 0.77 | KMT2A (0.52) | METAP2ALDH1A1ALPLMEN1KMT2A | |
| SCHEMBL6599673 | 0.77 | LMNA (0.32) | MEN1KMT2ALMNA | |
| SCHEMBL1260621 | 0.77 | LMNA (0.32) | MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253871-A1 | CORROSION-RESISTANT CONDUCTIVE STRUCTURE AND CORROSION-RESISTANT COATING COMPOSITION | TPK UNIVERSAL SOLUTIONS LIMITED (HK) | 2021-08-19 | — | — | US | claimed |
| CN-111192857-A | Corrosion-resistant conductive structure and corrosion-resistant coating composition | 宸盛光电有限公司 | 2020-05-22 | — | — | CN | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| CN-111601807-B | Exo-azaspiro inhibitors of MENIN-MLL interactions | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-26 | — | — | US | disclosed |
| CN-111943889-B | Bis-aryl amine compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-20210253871-A1 | CORROSION-RESISTANT CONDUCTIVE STRUCTURE AND CORROSION-RESISTANT COATING COMPOSITION | TPK UNIVERSAL SOLUTIONS LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| WO-2004046118-A2 | 2-4-(DI-PHENYL-AMINO)-PYRIMIDINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-4699915-A | ANTIULCER, ANTISECRETORY AGENTS | ISTITUTO DE ANGELI S.P.A. (IT) | 1987-10-13 | — | — | US | disclosed |
| US-4643993-A | ANTISECRETORY AGENTS; ANTIULCER AGENTS | ISTITUTO DE ANGELI S.P.A. (IT) | 1987-02-17 | — | — | US | disclosed |
| EP-0105534-B1 | SUBSTITUTED HETEROCYCLYLPHENYLSULPHONYL AND PHOSPHONYL AMIDINES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ISTITUTO DE ANGELI S.p.A. (IT) | 1986-10-08 | — | — | EP | disclosed |
| EP-0105534-A1 | Substituted heterocyclylphenylsulphonyl and phosphonyl amidines, process for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1984-04-18 | — | — | EP | disclosed |
| EP-0094727-A2 | Substituted heterocyclyl phenylformamidines, processes for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | METAP2 4072/4885ALDH1A1 1508/4885CYP3A4 3813/4885 |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | METAP2 4161/4885ALDH1A1 614/4885CYP3A4 2577/4885 |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | BMI1, MLLT1, EED | METAP2 3260/4885ALDH1A1 2583/4885CYP3A4 4259/4885 |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | METAP2 2228/4885ALDH1A1 2840/4885CYP3A4 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.